Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Fiche publication
Date publication
septembre 2022
Journal
Lupus
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé
Tous les auteurs :
Loiseau P, Foret T, DeFilippis EM, Risse J, Etienne AD, Dufrost V, Moulinet T, Erkan D, Devilliers H, Wahl D, Zuily S
Lien Pubmed
Résumé
Livedo is a well-known skin condition in patients with systemic lupus erythematosus (SLE) which correspond to small vessels involvement. The influence of antiphospholipid antibodies (aPL) on the occurrence of livedo is controversial. The aim of our study was to estimate the risk of livedo associated with aPL in patients with SLE.
Mots clés
Antiphospholipid antibodies, antiphospholipid syndrome, livedo, livedo racemosa, livedo reticularis, lupus anticoagulant, systemic lupus erythematosus
Référence
Lupus. 2022 09 15;:9612033221126852